Solid TumorPhase 1NCT04477057
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
A Phase 1 study testing HS-10241 in people with Solid Tumor, run by Jiangsu Hansoh Pharmaceutical Co., Ltd. at 1 site in China.
Trial summary
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Solid Tumor
- What is being tested?
- HS-10241
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 21 Jun 2019to 31 Dec 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed Informed Consent Form.
- Men or women aged more than or equal to (≥) 18 years, and less than (<) 75 years.
- Histologically or cytologically confirmed solid tumor, either refractory to standard therapy or for which no effective standard therapy is available.
- ECOG performance status of 0-1, estimated life expectancy greater than (>) three months.
- At least 1 lesion that has not previously been irradiated, that has not been chosen for biopsy during the study screening period, and that can be accurately measured at Baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), whichever is suitable for accurately repeated measurements.
- Females should be using adequate contraceptive measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at Screening:
Show all 10Show fewer
- Postmenopausal defined as age more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments.
- Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory.
- Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.
- Male patients should be willing to use barrier contraception (i.e., condoms).
Who cannot join
- Treatment with any of the following:
- Any cytotoxic chemotherapy, investigational agents, or anticancer drugs for the treatment of advanced solid tumor used for a previous treatment regimen or clinical study within 14 days of the first dose of study drug.
- Drugs with immunoregulatory indications within 7 days of the first dose of study drug.
- Medications that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug.
- Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) , unrecovered wound, ulcer, or fracture within 4 weeks of the first dose of study drug.
- Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study drug, with the exception of patients receiving radiation to > 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
Show all 45Show fewer
- Previous or current treatment with drugs targeting the c-MET/HGF pathway.
- Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment, with the exception of alopecia.
- Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 2 weeks prior to start of study treatment. Meningeal or brainstem metastases.
- Pleural or peritoneal effusion requiring clinical intervention (except for effusion stable at least 1 week after clinical intervention). Pericardial effusion (except for non-tumorous micro pericardial effusions).
- The tumor compresses or invades important surrounding organs (such as trachea, esophagus, superior vena cava, heart, and aorta, etc), or causes significant mediastinal displacement.
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the investigator's opinion, makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol such as active infection (e.g., hepatitis B, hepatitis C, or human immunodeficiency virus [HIV]). Screening for chronic conditions is not required.
- Any active infection requiring treatment or systemic anti-infective agent used in one week prior to first dose administration.
- Active hemoptysis, active diverticulitis, peritoneal abscess, gastrointestinal obstruction that requires clinical intervention.
- Medical history of arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, within 6 months prior to screening. Medical history of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months prior to screening.
- Varices of the esophagus or stomach that require immediate intervention (e.g., sclerotherapy).
- Any life-threatening bleeding events or Grade 3 or 4 gastrointestinal/varicose bleeding events requiring blood transfusion, endoscopy, or surgical treatment occurred within 3 months prior to enrollment.
- Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
- Any of the following cardiac criteria:
- Resting corrected QT interval (QTc) > 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
- Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 ms).
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
- Left ventricular ejection fraction (LVEF) ≤ 40%.
- Any newly diagnosed clinically important arrhythmia which is no reasonable reason other than tumor to explain within 3 months prior to enrollment.
- Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
- Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values:
- Absolute neutrophil count (ANC) <1.5×109 / L
- Platelet count <100×109 / L
- Hemoglobin <90 g/L（<9 g/dL）
- Alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases.
- Aspartate aminotransferase (AST) > 2.5 × ULN if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases.
- Total bilirubin (TBL) > 1.5 × ULN if no liver metastases or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases.
- Serum albumin (ALB) < 28 g/L, patients corrected by supplementation with human albumin should to exclude.
- Creatinine > 1.5 × ULN concurrent with creatinine clearance < 50 mL/min (measured or calculated by the Cockcroft-Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 × ULN.
- Urine protein ≥ 2+. When the Urine protein ≥ 2+ at baseline, 24-hour urine for collection, if the protein content in urine is less than 1g for 24 hours, inclusion is allowed.
- Refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study drug, or previous significant bowel resection that would preclude adequate absorption of HS-10241.
- History of hypersensitivity to any active or inactive ingredient of HS-10241 or to drugs with a similar chemical structure or class to HS-10241.
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
- Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
- History of other primary malignancies, excluding:
- Malignancies that have been recovered, have been inactive for ≥5 years prior to inclusion and have a very low risk of recurrence.
- Non-melanoma skin cancer or malignant freckle mole with adequate treatment and no evidence of disease recurrence.
- Carcinoma in situ with adequate treatment and no evidence of disease recurrence.
- Women who are breastfeeding or have a positive serum pregnancy test at Screening.
- Any uncontrolled metabolic dysfunction, local or systemic disease that is not caused by a malignant tumor, disease or symptoms secondary to the tumor, can lead to higher medical risk and/or uncertainty in the evaluation of survival.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 100021
shun Lu, MD, 021-22200000 ext. 2153, shun_lu@hotmail.com
Shenglin Ma
About this study
Official title: A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10241 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.
Read the detailed description
This is a phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of single and multiple doses of oral administration of HS-10241 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy. There is a dose-escalation study, which is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose and repeat doses of HS-10241 given once every day (QD). An alternative dosing schedule of twice every day (BID) may be investigated if the drug clearance of HS-10241 is faster than anticipated.
All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression once every 6 weeks, if the product is well tolerated and the subject has stable disease or better. As the disease progresses, survival follow-up is recommended bimonthly.
- Conditions
- Solid Tumor
- Being tested
- HS-10241
- Keywords
- phase 1, solid tumor, inhibitor of c-Met kinase
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HS-10241Drug
HS-10241 is a tablet in the form of 100 mg, oral, once daily.
| Study group | Role | What they receive |
|---|---|---|
| one arm | Other | one arm Receives: Drug: HS-10241 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of subjects with any dose limiting toxicity (DLT)
DLT is defined as one of the following HS-10241 related adverse event (AE) that occurs during the DLT period, excluding AE assessed by investigator exclusively related to subject's underlying disease or medical condition (graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0): Grade 4 hematological toxicity and Grade ≥ 3 non-hematological toxicity.
Measured: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).
To determine the maximum tolerated dose (MTD)
MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT.
Measured: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).
Secondary outcomes (15)
Incidence and severity of treatment-emergent adverse events
Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, RECIST1.1, and NCI CTCAE v5.0.
Measured: From baseline until 28 days after the last dose
Observed maximum plasma concentration (Cmax) after single dose of HS-10241
In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10241 on Day 1 to Day 6.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10241
At multiple-dose, Cmax ss will be obtained on Day 1 of dosing in the second 21-Day cycle of therapy.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 21-Day cycle of therapy
Time to reach maximum plasma concentration (Tmax) after single dose of HS-10241
In the study of single-dose, Tmax will be obtained following administration of a single oral dose of HS-10241 on Day 1 to Day 6.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Time to reach maximum plasma concentration (Tmax) after multiple dose of HS-10241
At multiple-dose, Tmax will be obtained on Day 1 of dosing in the second 21-Day cycle of therapy.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 21-Day cycle of therapy
Apparent terminal half-life (t1/2) after single dose of HS-10241
Apparent terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Area under plasma concentration versus time curve from zero to the 24 hour sampling time (AUC0-24) after single dose of HS-10241
Area under the plasma concentration versus time curve from time zero to the 24 hour sampling time 24 at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-24 was to be calculated according to the mixed log-linear trapezoidal rule.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10241
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-10241
AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Measured: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
To further evaluation of the anti-tumor activity of HS-10241 by assessment of objective response rate (ORR)
Anti-tumoral efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors at baseline (Day -28 to -1). For patients that continue on repeat 21-Day cycles after the primary evaluation period, progression will be assessed after each 6 weeks of therapy. ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.
Measured: 0-360day
Duration of response of HS-10241
Duration of response assessed by RECIST 1.1. Duration of response was defined as the time from when the criteria for CR or PR were first met to the occurrence of a objective disease progression (PD) or death.
Measured: 0-360day
Time to objective response of HS-10241
Objective response was assessed by RECIST 1.1.
Measured: 0-360day
Disease control rate of HS-10241
Objective response was assessed by RECIST 1.1 thereby to evaluate disease control rate. Disease control was defined as the percentage of patients who have a best overall response (confirmd CR, PR, or stable disease for at least 5 weeks).
Measured: 0-360day
Deepness of response of HS-10241
Objective response was assessed by RECIST 1.1 thereby to evaluate deepness of response. Depth of response was defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of new lesions, or progression of non-target lesions compared with baseline.
Measured: 0-360day
Progression-free survival of HS-10241
Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival. Progression-free survival was defined as the time from date of first dose until the documention of objective disease progression (PD) or death from any cause in the absence of progression (whichever occurred first), regardless of whether they subsequently received non-study anti-cancer therapy.
Measured: 0-360day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2020
- Study start21 Jun 2019
- Primary completion31 Dec 2020 (estimated)
- Study completion31 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid TumorStudies of the same condition, open and under way.
- More trials run by Jiangsu Hansoh Pharmaceutical Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Shun Lu, Principal investigator, Shanghai Chest HospitalShenglin Ma, Principal investigator, First People's Hospital of HangzhouDeguang Mu, Principal investigator, Zhejiang Provincial People's HospitalJianhua Chen, Principal investigator, Hunan Cancer HospitalXiaorong Dong, Principal investigator, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyXiaoju Zhang, Principal investigator, Henan Provincial People's HospitalXingya Li, Principal investigator, The First Affiliated Hospital of Zhengzhou University7Yubiao Guo, Principal investigator, First Affiliated Hospital, Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04477057
- Sponsor's protocol ID
- HS-10241-101-CN
- Status last verified
- Mar 2020
- First submitted
- 27 Apr 2020
- Last updated
- 20 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10241 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Progressed Following Prior Therapy
- ClinicalTrials.gov ID
- NCT04477057
- Acronym / sponsor ID
- HS-10241-101-CN
- Conditions
- Solid Tumor
- Keywords
- phase 1, solid tumor, inhibitor of c-Met kinase
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 21 Jun 2019 (actual)
- Primary completion
- 31 Dec 2020 (estimated)
- Study completion
- 31 Dec 2021 (estimated)
- First posted
- 20 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth. This study is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-10241 at single dose and multiple doses.
Detailed description
This is a phase 1, open-label, multicenter study to evaluate safety, tolerability, pharmacokinetics, and efficacy of single and multiple doses of oral administration of HS-10241 in patients with locally advanced or metastatic solid tumors who have progressed following prior therapy. There is a dose-escalation study, which is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose and repeat doses of HS-10241 given once every day (QD). An alternative dosing schedule of twice every day (BID) may be investigated if the drug clearance of HS-10241 is faster than anticipated.
All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression once every 6 weeks, if the product is well tolerated and the subject has stable disease or better. As the disease progresses, survival follow-up is recommended bimonthly.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| one arm | Other | Drug: HS-10241one arm |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Signed Informed Consent Form.
- Men or women aged more than or equal to (≥) 18 years, and less than (<) 75 years.
- Histologically or cytologically confirmed solid tumor, either refractory to standard therapy or for which no effective standard therapy is available.
- ECOG performance status of 0-1, estimated life expectancy greater than (>) three months.
- At least 1 lesion that has not previously been irradiated, that has not been chosen for biopsy during the study screening period, and that can be accurately measured at Baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), whichever is suitable for accurately repeated measurements.
Key exclusion criteria (45 listed)
- Treatment with any of the following:
- Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment, with the exception of alopecia.
- Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 2 weeks prior to start of study treatment. Meningeal or brainstem metastases.
- Pleural or peritoneal effusion requiring clinical intervention (except for effusion stable at least 1 week after clinical intervention). Pericardial effusion (except for non-tumorous micro pericardial effusions).
- The tumor compresses or invades important surrounding organs (such as trachea, esophagus, superior vena cava, heart, and aorta, etc), or causes significant mediastinal displacement.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HS-10241HS-10241 is a tablet in the form of 100 mg, oral, once daily. | Drug | one arm |
Primary outcome
Number of subjects with any dose limiting toxicity (DLT)
Time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).
DLT is defined as one of the following HS-10241 related adverse event (AE) that occurs during the DLT period, excluding AE assessed by investigator exclusively related to subject's underlying disease or medical condition (graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0): Grade 4 hematological toxicity and Grade ≥ 3 non-hematological toxicity.
To determine the maximum tolerated dose (MTD)
Time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).
MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT.
15 secondary outcomes
Incidence and severity of treatment-emergent adverse events
Time frame: From baseline until 28 days after the last dose
Observed maximum plasma concentration (Cmax) after single dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 21-Day cycle of therapy
Time to reach maximum plasma concentration (Tmax) after single dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Time to reach maximum plasma concentration (Tmax) after multiple dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24 hours post-dose on Day 1 of dosing in the second 21-Day cycle of therapy
Apparent terminal half-life (t1/2) after single dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Area under plasma concentration versus time curve from zero to the 24 hour sampling time (AUC0-24) after single dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-10241
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24,48, 72,120 hours post-dose on Day 1 single dose
To further evaluation of the anti-tumor activity of HS-10241 by assessment of objective response rate (ORR)
Time frame: 0-360day
Duration of response of HS-10241
Time frame: 0-360day
Time to objective response of HS-10241
Time frame: 0-360day
Disease control rate of HS-10241
Time frame: 0-360day
Deepness of response of HS-10241
Time frame: 0-360day
Progression-free survival of HS-10241
Time frame: 0-360day
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2020.
- Individual participant dataSharing planned: No
Related trials for Solid Tumor
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Neoplasms
Active, not recruitingPhase 3
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Solid Tumors
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shun Lu principal investigator
Shanghai Chest Hospital
Shenglin Ma principal investigator
First People's Hospital of Hangzhou
Deguang Mu principal investigator
Zhejiang Provincial People's Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing HS-10241 in people with Solid Tumor, run by Jiangsu Hansoh Pharmaceutical Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 45 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Tianyu Sun (13817295181, sunty@hspharm.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of subjects with any dose limiting toxicity (DLT) (time frame: From the single dose to the last dose of the first cycle defined as 21 days of multiple dosing (4 weeks).). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2020; AzTrials last refreshed its copy on 8 Nov 2026.